logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Economic evaluation of allogeneic bone marrow transplantation : A rudimentary model to generate estimates for the timely formulation of clinical policy.

    Article - En anglais

    Purpose 

    To provide an evidence-based approach to the formulation of clinical policy with respect to allogeneic bone marrow transplantation (BMT) that involves perceived trade offs between two major factors : costs and consequences.

    The report also highlights key informational deficiencies.

    Patients and Methods 

    Adults with acute myeloid leukemia (AML) in second complete remission (2CR) and those with acute lymphoblastic leukemia (ALL) in first complete remission (1CR) were assigned to BMT or control groups solely on the availability of a suitable donor.

    All hospital-borne costs were estimated, based on services used according to manual chart review, in four categories : diagnostic and therapeutic costs, professional fees, drug costs, and ward costs.

    Incremental costs and incremental life-years were calculated, and the quotient determined a cost per life-year gained by BMT for AML (2CR) and ALL (1CR).

    Results 

    The incremental cost (in 1992 Canadian dollars) per life-year gained by BMT (cost-effectveness) for AML (2CR) was $29,200 ; and for ALL (1CR) it was minus $29,200.

    Conclusion 

    For AML (2CR), allogeneic BMT creates better outcomes than standard treatment, but is more costly.

    For ALL (1CR), both the costs and outcomes are similar for BMT and standard therapy.

    Quality adjustments made to life-years gained did not change these conclusions.

    Mots-clés Pascal : Leucémie myéloblastique, Leucémie lymphoblastique, Adulte, Homme, Homogreffe, Cellule hématopoïétique, Traitement, Analyse coût efficacité, Economie santé, Aigu, Moelle osseuse, Hémopathie maligne, Lymphoprolifératif syndrome, Greffe, Transfusion

    Mots-clés Pascal anglais : Acute myelocytic leukemia, Acute lymphocytic leukemia, Adult, Human, Homograft, Hematopoietic cell, Treatment, Cost efficiency analysis, Health economy, Acute, Bone marrow, Malignant hemopathy, Lymphoproliferative syndrome, Graft, Transfusion

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 96-0255382

    Code Inist : 002B27D02. Création : 199608.